Intellia Therapeutics (NTLA) PT Raised to $20 at Wedbush, Following Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $12.31 +3.79%
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Wedbush analyst David Nierengarten raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $20.00 (from $16.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intellia completes enrollment in Phase 3 nex-z trial for nerve disease
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
- Sprout Social Inc. (SPT) PT Raised to $15 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
